Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.44 |
| ▸ | CTSD | P07339 | 3/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381064 | 0.86 | BACE1 (0.54) | BACE1KCNH2CTSDBACE2 | |
| SCHEMBL2381074 | 0.86 | BACE1 (0.54) | BACE1KCNH2CTSDBACE2 | |
| SCHEMBL12236843 | 0.85 | BACE1 (0.42) | BACE1KCNH2CTSDBACE2 | |
| SCHEMBL2524963 | 0.84 | BACE1 (0.60) | BACE1KCNH2CTSDBACE2 | |
| SCHEMBL2524959 | 0.84 | BACE1 (0.60) | BACE1KCNH2CTSDBACE2 | |
| SCHEMBL12235935 | 0.80 | BACE1 (0.60) | BACE1KCNH2CTSDBACE2 | |
| SCHEMBL2523986 | 0.77 | BACE1 (0.53) | BACE1CTSD | |
| SCHEMBL2523987 | 0.77 | BACE1 (0.53) | BACE1CTSD | |
| SCHEMBL12213452 | 0.75 | BACE1 (0.67) | BACE1KCNH2CTSDBACE2 | |
| SCHEMBL15418814 | 0.75 | BACE1 (0.50) | BACE1KCNH2CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115928-A1 | AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | BACE1 1/4885KCNH2 3091/4885CTSD 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.